Why should you invest in this smallcase?

Indian pharmaceutical sector is estimated to grow to USD 55 billion by 2020, thereby emerging as the sixth largest pharmaceutical market globally by absolute size.

  • Branded generics dominate the pharmaceuticals market, constituting nearly 80 per cent of the market share in terms of revenues
  • The sector’s revenues are expected to grow by 8% y-o-y through fiscal 2020
  • Pharma sector is expected to generate 58,000 additional job opportunities by 2025
  • Indian companies received 304 Abbreviated New Drug Application (ANDA) approvals from the USFDA in 2017. And account for around 30% of the USD 70-80 billion US generics market
  • A large pipe-line of high-value drugs as well as decline in regulatory alerts for larger companies is expected to drive growth

This smallcase comprises pharmaceutical and life sciences companies to allow investors to efficiently track and invest in the pharma sector.

Know how this smallcase was created


Download key points about this smallcase

Created by smallcase Research

Past PerformancePerformance vs 

one timemonthly sip
one timemonthly sip

Current value of Returns on ₹ 100 invested once 4 years ago would beare

₹ 78.20
NIFTY Midcap17.54%
₹ 117.54
NIFTY Midcap
Comparing:  smallcase with NIFTY Midcap

Past performance doesn't guarantee future returns & is inclusive of all rebalances.Download chart